Case Studies

SFJ formed a partnership with Eisai to develop the oral multikinase inhibitor, lenvatinib for the treatment of thyroid cancer. The target group was patients with differentiated thyroid cancer (the most common type of thyroid cancer, responsible for 90% of cases) who were refractory to treatment with radioactive iodine. The prognosis for these patients was poor with a 10 year survival rate of 10%.

At the time of the investment, Eisai had shown encouraging Phase II data in the target patient population. A global Phase III trial had started but no data was available. In March 2011, the Fukushima power plant in Japan suffered a nuclear disaster following a tsunami. Exposure to radiation is a known risk factor for thyroid cancer and the Japanese FDA equivalent was keenly aware of this. We felt that positive clinical data in a radioactive-iodine-resistant thyroid cancer would be likely to receive a favourable review.

Deal progress

The pivotal trial ran to plan, producing highly impressive results. Progression free survival in the lenvatinib-treated patients was 18.4 months, compared with 3.6 months in the placebo-treated patients, a fivefold increase. Based on the unmet need for this indication, the FDA granted the marketing application Priority Review and approved it in February 2015, triggering a significant payment to EFV-Thyroid. Subsequently, the drug was approved in both Japan and Europe.

BACK
Business
Clinical Co-Development
Indication
Thyroid Cancer
Stage
Now approved; available for patients
Initial Investment
September 2011
Outcome
Approved in the US in February 2013 and later in Japan and Europe

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Case Study

SFJ formed a partnership with Eisai to develop the oral multikinase inhibitor, lenvatinib for the treatment of thyroid cancer. The target group was patients with differentiated thyroid cancer (the most common type of thyroid cancer, responsible for 90% of cases) who were refractory to treatment with radioactive iodine. The prognosis for these patients was poor with a 10 year survival rate of 10%.

At the time of the investment, Eisai had shown encouraging Phase II data in the target patient population. A global Phase III trial had started but no data was available. In March 2011, the Fukushima power plant in Japan suffered a nuclear disaster following a tsunami. Exposure to radiation is a known risk factor for thyroid cancer and the Japanese FDA equivalent was keenly aware of this. We felt that positive clinical data in a radioactive-iodine-resistant thyroid cancer would be likely to receive a favourable review.

Deal progress

The pivotal trial ran to plan, producing highly impressive results. Progression free survival in the lenvatinib-treated patients was 18.4 months, compared with 3.6 months in the placebo-treated patients, a fivefold increase. Based on the unmet need for this indication, the FDA granted the marketing application Priority Review and approved it in February 2015, triggering a significant payment to EFV-Thyroid. Subsequently, the drug was approved in both Japan and Europe.

Business
Clinical Co-Development
Indication
Thyroid Cancer
Stage
Now approved; available for patients
Initial Investment
September 2011
Outcome
Approved in the US in February 2013 and later in Japan and Europe
BACK
 
Copyright Abingworth 2017